C92.60

HCC Category Mapping

What This Code Means

A specific type of acute myeloid leukemia with a chromosomal abnormality (11q23) that has not responded adequately to initial treatment.

Coding Tips

• •The 11q23-abnormality is a cytogenetic finding that should be documented in the pathology report
• •This code indicates the patient has not achieved remission status after treatment attempts

Clinical Significance

Acute myeloid leukemia with 11q23-abnormality represents a cytogenetically defined AML subtype involving rearrangements of the KMT2A (MLL) gene at chromosome 11q23. This abnormality is found in approximately 5-10% of adult AML cases and is associated with monocytic differentiation, extramedullary disease, and intermediate-to-poor prognosis depending on the specific fusion partner. The 'not in remission' designation indicates active disease not responding to treatment.

Documentation Requirements

• ✓Documentation must confirm the 11q23/KMT2A rearrangement by cytogenetics or FISH, specifying the fusion partner gene when identified (common partners include MLLT3/AF9, MLLT1/ENL, MLLT4/AF6).
• ✓Active disease status, blast percentage, and monocytic component should be documented.
• ✓Treatment response assessment and current therapeutic plan must be recorded.
• ✓Additional molecular mutations (FLT3, NPM1) should be documented when tested.

Commonly Confused Codes